Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


25.06.2018

1 BMC Cancer
1 Cancer Lett
1 Cancer Res
1 J Immunol
1 J Pediatr Hematol Oncol
6 Leuk Lymphoma
6 Leuk Res
2 Leukemia
3 N Engl J Med
1 Oncol Rep
1 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. CORDAS DOS SANTOS DM, Eilers J, Sosa Vizcaino A, Orlova E, et al
    MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-kappaB.
    BMC Cancer. 2018;18:663.
    PubMed     Text format     Abstract available


    Cancer Lett

  2. LEE YC, Wang LJ, Huang CH, Shi YJ, et al
    ABT-263-induced MCL1 upregulation depends on autophagy-mediated 4EBP1 downregulation in human leukemia cells.
    Cancer Lett. 2018 Jun 15. pii: S0304-3835(18)30417.
    PubMed     Text format     Abstract available


    Cancer Res

  3. OSUMI T, Tsujimoto SI, Tamura M, Uchiyama M, et al
    Recurrent RARB Translocations in Acute Promyelocytic Leukemia lacking RARA Translocation.
    Cancer Res. 2018 Jun 19. pii: 0008-5472.CAN-18-0840.
    PubMed     Text format     Abstract available


    J Immunol

  4. STERNER RM, Kremer KN, Dudakovic A, Westendorf JJ, et al
    Tissue-Nonspecific Alkaline Phosphatase Is Required for MC3T3 Osteoblast-Mediated Protection of Acute Myeloid Leukemia Cells from Apoptosis.
    J Immunol. 2018 Jun 18. pii: jimmunol.1800174. doi: 10.4049/jimmunol.1800174.
    PubMed     Text format     Abstract available


    J Pediatr Hematol Oncol

  5. PALEN K, Thakar M, Johnson BD, Gershan JA, et al
    Bone Marrow-derived CD8+ T Cells From Pediatric Leukemia Patients Express PD1 and Expand Ex Vivo Following Induction Chemotherapy.
    J Pediatr Hematol Oncol. 2018 Jun 14. doi: 10.1097/MPH.0000000000001244.
    PubMed     Text format     Abstract available


    Leuk Lymphoma

  6. YAMAMOTO K, Yakushijin K, Ichikawa H, Kakiuchi S, et al
    Expression of a novel ZMYND11/MBTD1 fusion transcript in CD7(+)CD56(+) acute myeloid leukemia with t(10;17)(p15;q21).
    Leuk Lymphoma. 2018 Jun 18:1-5. doi: 10.1080/10428194.2018.1464157.
    PubMed     Text format    

  7. PAPAGEORGIOU SG, Diamantopoulos MA, Kontos CK, Bouchla A, et al
    MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Jun 18:1-10. doi: 10.1080/10428194.2018.1461861.
    PubMed     Text format     Abstract available

  8. STRATI P, Gabutti C, Thompson PA, Kontoyiannis DP, et al
    Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Jun 18:1-3. doi: 10.1080/10428194.2018.1474527.
    PubMed     Text format    

  9. CRASSINI K, Pyke T, Shen Y, Stevenson WS, et al
    Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells.
    Leuk Lymphoma. 2018 Jun 18:1-12. doi: 10.1080/10428194.2018.1455974.
    PubMed     Text format     Abstract available

  10. THAN H, Lye WK, Sng C, Allen JC Jr, et al
    BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients.
    Leuk Lymphoma. 2018 Jun 19:1-4. doi: 10.1080/10428194.2018.1461863.
    PubMed     Text format    

  11. CHEN CI, Paul H, Le LW, Wei EN, et al
    A phase 2 study of ofatumumab (Arzerra((R))) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2018 Jun 19:1-9. doi: 10.1080/10428194.2018.1468892.
    PubMed     Text format     Abstract available


    Leuk Res

  12. GAVILLET M, Spertini O, Blum S
    Pseudo Chediak-Higashi anomaly in blasts from acute lymphoblastic leukemia.
    Leuk Res. 2018;70:87-90.
    PubMed     Text format    

  13. LEE SE, Choi SY, Kim SH, Jootar S, et al
    Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib.
    Leuk Res. 2018;70:100-105.
    PubMed     Text format     Abstract available

  14. VULAJ V, Perissinotti AJ, Uebel JR, Nachar VR, et al
    The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia.
    Leuk Res. 2018;70:91-96.
    PubMed     Text format     Abstract available

  15. WANG W, Routbort MJ, Loghavi S, Tang Z, et al
    Characterization of chronic myelomonocytic leukemia with TP53 mutations.
    Leuk Res. 2018;70:97-99.
    PubMed     Text format    

  16. LIU C, Wei H, Yao X, Liu B, et al
    Retraction notice to "Arsenic Trioxide Inhibits Proliferation and Induced apoptosis of Leukemia Stem Cells with Drug Resistance " [LR 69 (2018) 66-71].
    Leuk Res. 2018;69:103.
    PubMed     Text format    

  17. BRYANT AL, Drier SW, Lee S, Bennett AV, et al
    A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia.
    Leuk Res. 2018;70:106-116.
    PubMed     Text format     Abstract available


    Leukemia

  18. GEBHARD C, Glatz D, Schwarzfischer L, Wimmer J, et al
    Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association.
    Leukemia. 2018 Jun 20. pii: 10.1038/s41375-018-0165.
    PubMed     Text format     Abstract available

  19. SUTTORP M, Schulze P, Glauche I, Gohring G, et al
    Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
    Leukemia. 2018 Jun 20. pii: 10.1038/s41375-018-0179.
    PubMed     Text format     Abstract available


    N Engl J Med


  20. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    N Engl J Med. 2018;378:2442-2443.
    PubMed     Text format    

  21. ULRICH BC
    Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    N Engl J Med. 2018;378:2442.
    PubMed     Text format    

  22. MAUVIEUX L, Miguet L, Fornecker L
    Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    N Engl J Med. 2018;378:2442-3.
    PubMed     Text format    


    Oncol Rep

  23. ZHANG XH, Yang L, Liu XJ, Zhan Y, et al
    Association between methylation of tumor suppressor gene SOCS1 and acute myeloid leukemia.
    Oncol Rep. 2018 Jun 19. doi: 10.3892/or.2018.6508.
    PubMed     Text format     Abstract available


    PLoS One

  24. BLUME JD, D'Agostino McGowan L, Dupont WD, Greevy RA Jr, et al
    Second-generation p-values: Improved rigor, reproducibility, & transparency in statistical analyses.
    PLoS One. 2018;13:e0188299.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  25. KANJEE U, Gruring C, Chaand M, Lin KM, et al
    CRISPR/Cas9 knockouts reveal genetic interaction between strain-transcendent erythrocyte determinants of Plasmodium falciparum invasion.
    Proc Natl Acad Sci U S A. 2017;114:E9356-E9365.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: